Plaque Psoriasis Injection study

We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.

About Plaque Psoriasis

Psoriasis is a chronic inflammatory skin disease characterized by raised, red oval plaques on the skin with silvery scales. Lesions are typically painful or itchy and can be associated with a high degree of morbidity. Plaques on visible skin have a particular impact on physical, sexual, psychosocial, and even economic status; associated with reduced levels of employment and income. Psoriasis is more than a superficial disease, with 30% of patients having joint involvement, and a high correlation between psoriasis and obesity, diabetes, depression, metabolic syndrome, and cardiovascular risk.

About the Study

This is an 44-week long study that will assess the safety and efficacy of Amlitelimab vs placebo used to treat plaque psoriasis.

Am I Eligible?

  • Must be 18 or older
  • Diagnosed for a minimum of 1 year
  • 10 palm prints of psoriasis area on body (can you cover 10 areas of your body with your palm of affected area)¬†
  • If currently taking medication to treat psoriasis, washout will be required prior to enrollment (length of washout depends on current medication)

What Should I Expect?

  • 10 office visits over a 44 week period.

Other Information 

  • Compensation may be available for time/travel

If you are interested in participating in one of these studies, please provide your contact information below. If you are a qualified candidate, a representative from our research department will be in touch with you.

Volunteer for this study!

  • This field is for validation purposes and should be left unchanged.